Vanta Bioscience: peers
Vanta Bioscience beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Vanta Bioscience, Medinova Diagnostic Services, Dolphin Medical Services Limited, Dr Habeebullah Life Sciences Limited, Scandent Imaging, Choksi Laboratories, Aspira Pathlab & Diagnostics Limited, FOXO Technologies Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Vanta Biosciencebase VANTABIO.BO · 🇮🇳 IN Percentile in Healthcare Percentile in India | Medinova Diagnostic Services MEDINOV.BO · 🇮🇳 IN Percentile in Healthcare Percentile in India | Dolphin Medical Services Limited DOLPHMED.BO · 🇮🇳 IN Percentile in Healthcare Percentile in India | Dr Habeebullah Life Sciences Limited DRHABEEB.BO · 🇮🇳 IN Percentile in Healthcare Percentile in India | Scandent Imaging SCANDENT.BO · 🇮🇳 IN Percentile in Healthcare Percentile in India | Choksi Laboratories CHOKSILA.BO · 🇮🇳 IN Percentile in Healthcare Percentile in India | Aspira Pathlab & Diagnostics Limited ASPIRA.BO · 🇮🇳 IN Percentile in Healthcare Percentile in India | FOXO Technologies Inc. FOXO · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $2 Mlast known, Mar 8, 2026 · Market dataLast known value: no current one6th of 8 | $3 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one5th of 8 | $1 Mlast known, Mar 8, 2026 · Market dataLast known value: no current one8th of 8 | $5 Mlast known, Jan 7, 2022 · Market dataLast known value: no current one3rd of 8 | $5 Mlast known, Dec 25, 2022 · Market dataLast known value: no current one3rd of 8 | $7 Mlast known, Mar 8, 2026 · Market dataLast known value: no current one1st of 8 | $7 Mlast known, Mar 8, 2026 · Market dataLast known value: no current one1st of 8 | $2 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one6th of 8 | $4 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | —— | —— | —— | —— | —— | —— | $16 MFY2025 · SEConly one with it | $16 M— |
| Net income (Higher is better) | —— | —— | —— | —— | —— | —— | —— | $-12 MFY2025 · SEConly one with it | $-12 M— |
| Employees (Better neither way: ranked highest first) | —— | —— | —— | —— | —— | —— | —— | 192March 10, 2026 · Profileonly one with it | 192— |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | ———— | +304.2%FY2025 · SEConly one with it97th99th | +304.2%— |
| Margins and returns | |||||||||
| Operating margin (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | ———— | -63.1%FY2025 · SEConly one with it28th13th | -63.1%— |
| Net margin (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | ———— | -75.9%FY2025 · SEConly one with it26th12th | -75.9%— |
| Free cash flow margin (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | ———— | -24.0%FY2025 · SEConly one with it36th16th | -24.0%— |
| Return on equity (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | ———— | -151.0%FY2025 · SEConly one with it16th7th | -151.0%— |
| Financial strength | |||||||||
| Interest cover (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | ———— | -3.0×FY2025 · SEConly one with it62nd35th | -3.0×— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | —— | —— | —— | —— | —— | —— | 1 of 8FY2025 · Scorecardonly one with it | 13% passed— |
| Growth checks (Higher is better) | —— | —— | —— | —— | —— | —— | —— | 1 of 1FY2025 · Scorecardonly one with it | 100% passed— |
| Profitability checks (Higher is better) | —— | —— | —— | —— | —— | —— | —— | 0 of 4FY2025 · Scorecardonly one with it | 0% passed— |
| Financial health checks (Higher is better) | —— | —— | —— | —— | —— | —— | —— | 0 of 3FY2025 · Scorecardonly one with it | 0% passed— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Vanta Bioscience: National Stock Exchange of India, daily market-cap file; Medinova Diagnostic Services: National Stock Exchange of India, daily market-cap file; Dolphin Medical Services Limited: National Stock Exchange of India, daily market-cap file; Dr Habeebullah Life Sciences Limited: National Stock Exchange of India, daily market-cap file; Scandent Imaging: National Stock Exchange of India, daily market-cap file; Choksi Laboratories: National Stock Exchange of India, daily market-cap file; Aspira Pathlab & Diagnostics Limited: National Stock Exchange of India, daily market-cap file; FOXO Technologies Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Vanta Bioscience | — | — | — |
| Medinova Diagnostic Services | — | — | — |
| Dolphin Medical Services Limited | — | — | — |
| Dr Habeebullah Life Sciences Limited | — | — | — |
| Scandent Imaging | — | — | — |
| Choksi Laboratories | — | — | — |
| Aspira Pathlab & Diagnostics Limited | — | — | — |
| FOXO Technologies Inc. | -63.1%FY2025 | 28th percentile in Healthcaremedian -7.7%, 674 companies | 13th percentile in USAmedian 3.5%, 2,594 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
Ranks need two fiscal years with the figure for at least two of these companies.
| Fiscal year | Vanta Bioscience | Medinova Diagnostic Services | Dolphin Medical Services Limited | Dr Habeebullah Life Sciences Limited | Scandent Imaging | Choksi Laboratories | Aspira Pathlab & Diagnostics Limited | FOXO Technologies Inc. |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | — | — | — | — | — | — | $16 MSEC |
| 2024 | — | — | — | — | — | — | — | $4 MSEC |
| 2023 | — | — | — | — | — | — | — | $0 MSEC |
| 2021 | — | — | — | — | — | — | — | $0 MSEC |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Vanta Bioscience#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Medinova Diagnostic ServicesMEDINOV.BO · 🇮🇳 IndiaSame industry: Diagnostics and Research · Similar size: $3 M market cap against $2 M · Same country: IndiaMarket cap $3 M (last known, Jul 30, 2023)92 of 100 (industry or sector 50 + size 27 + country 15)In the group
- Dolphin Medical Services LimitedDOLPHMED.BO · 🇮🇳 IndiaSame industry: Diagnostics and Research · Similar size: $1 M market cap against $2 M · Same country: IndiaMarket cap $1 M (last known, Mar 8, 2026)90 of 100 (industry or sector 50 + size 26 + country 15)In the group
- Dr Habeebullah Life Sciences LimitedDRHABEEB.BO · 🇮🇳 IndiaSame industry: Diagnostics and Research · Similar size: $5 M market cap against $2 M · Same country: IndiaMarket cap $5 M (last known, Jan 7, 2022)89 of 100 (industry or sector 50 + size 24 + country 15)In the group
- Scandent ImagingSCANDENT.BO · 🇮🇳 IndiaSame industry: Diagnostics and Research · Similar size: $5 M market cap against $2 M · Same country: IndiaMarket cap $5 M (last known, Dec 25, 2022)89 of 100 (industry or sector 50 + size 24 + country 15)In the group
- Choksi LaboratoriesCHOKSILA.BO · 🇮🇳 IndiaSame industry: Diagnostics and Research · Similar size: $7 M market cap against $2 M · Same country: IndiaMarket cap $7 M (last known, Mar 8, 2026)87 of 100 (industry or sector 50 + size 22 + country 15)In the group
- Aspira Pathlab & Diagnostics LimitedASPIRA.BO · 🇮🇳 IndiaSame industry: Diagnostics and Research · Similar size: $7 M market cap against $2 M · Same country: IndiaMarket cap $7 M (last known, Mar 8, 2026)87 of 100 (industry or sector 50 + size 22 + country 15)In the group
- FOXO Technologies Inc.FOXO · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $2 M market cap against $2 M · Ratios of the last two fiscal years on fileMarket cap $2 M (last known, Jan 5, 2024) · revenue $16 M (year to December 2025)85 of 100 (industry or sector 50 + size 30 + figures on file 5)In the group
- Virax Biolabs Group LimitedVRAX · 🇬🇧 UKSame industry: Diagnostics and Research · Similar size: $2 M market cap against $2 M · Ratios of the last two fiscal years on fileMarket cap $2 M (Aug 1, 2026) · revenue $0 M (year to March 2025)85 of 100 (industry or sector 50 + size 30 + figures on file 5)+ Add
- CapForce Inc.CFOR · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $4 M market cap against $2 M · Ratios of the last two fiscal years on fileMarket cap $4 M (last known, Jan 5, 2024) · revenue $30 M (year to December 2025)80 of 100 (industry or sector 50 + size 26 + figures on file 5)+ Add
- Co-Diagnostics, Inc.CODX · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $4 M market cap against $2 M · Ratios of the last two fiscal years on fileMarket cap $4 M (Oct 30, 2026) · revenue $1 M (year to December 2025)80 of 100 (industry or sector 50 + size 25 + figures on file 5)+ Add
- Prostatype Genomics AB (publ)PROGEN.ST · 🇸🇪 SwedenSame industry: Diagnostics and Research · Similar size: $2 M market cap against $2 MMarket cap $2 M (last known, Jan 5, 2024)80 of 100 (industry or sector 50 + size 30)+ Add
- Motus GI Holdings, Inc.MOTS · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $2 M market cap against $2 MMarket cap $2 M (last known, Jan 5, 2024)80 of 100 (industry or sector 50 + size 30)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.